Oncotelic Aligns with Biotech M&A Trend for Late-Stage Assets
February 18, 2026 — Oncotelic Therapeutics featured in BioMedWire editorial on biotech M&A trends focusing on late-stage oncology & CNS assets. Learn about its OT-101 platform & strategic position.